• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety of Short-Term Use of Dabigatran or Rivaroxaban for Direct-Current Cardioversion in Patients With Atrial Fibrillation and Atrial Flutter
In conclusion, the use of short-term dabigatran or rivaroxaban therapy for DCCV of AF appears safe.
Source: The American Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Ajay Yadlapati, Christopher Groh, Rod Passman Tags: Arrhythmias and Conduction Disturbances Source Type: research

Impact of Dual Antiplatelet Therapy on Outcomes Among Aspirin-Resistant Patients Following Coronary Artery Bypass Grafting
This study was designed to define the impact of dual antiplatelet therapy (dAPT) on clinical outcomes among aspirin-resistant patients who underwent coronary artery surgery. We randomly assigned 219 aspirin-resistant patients according to multiple electrode aggregometry to receive clopidogrel (75 mg) plus aspirin (300 mg) or aspirin-monotherapy (300 mg). The primary end point was a composite outcome of all-cause death, nonfatal myocardial infarction, stroke, or cardiovascular hospitalization assessed at 6 months postoperatively. The primary end point occurred in 6% of patients assigned to dAPT and 10% of patients rando...
Source: The American Journal of Cardiology - March 3, 2014 Category: Cardiology Authors: Hrvoje Gasparovic, Mate Petricevic, Tomislav Kopjar, Zeljko Djuric, Lucija Svetina, Bojan Biocina Tags: Coronary Artery Disease Source Type: research

Performance of Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
In conclusion, the performance of ATRIA, HAS-BLED, mOBRI, and REACH scores in predicting bleeding complications in this high-risk patient subset was useless.
Source: The American Journal of Cardiology - April 3, 2014 Category: Cardiology Authors: Tuomas Kiviniemi, Marja Puurunen, Axel Schlitt, Andrea Rubboli, Pasi Karjalainen, Saila Vikman, Matti Niemelä, Heli Lahtela, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Coronary Artery Disease Source Type: research

Impact of Female Gender on Bleeding Complications After Transradial Coronary Intervention (from the Korean Transradial Coronary Intervention Registry)
This study aimed to investigate the impact of gender on clinical outcomes and bleeding complications after transradial coronary intervention (TRI). The Korean TRI registry is a retrospective multicenter registry with 4,890 patients who underwent percutaneous coronary intervention in 2009 at 12 centers. To compare clinical outcomes and bleeding complications between the male and female groups, we performed a propensity score matching in patients who received TRI. A total of 1,194 patients (597 in each group) were studied. The primary outcome was 1-year major adverse cardiac events, including all-cause mortality, myocardial ...
Source: The American Journal of Cardiology - April 3, 2014 Category: Cardiology Authors: Jeoung-Sook Shin, Seung-Jea Tahk, Hyoung-Mo Yang, Myeong-Ho Yoon, So-Yeon Choi, Byoung-Joo Choi, Hong-Seok Lim, You-Hong Lee, Kyoung-Woo Seo, Se-Jun Park, Yong-Woo Choi, Junghan Yoon, Young Jin Youn, Byung Ryeol Cho, Kwang Soo Cha, Kyoo Rok Han, Min Su Hy Tags: Coronary Artery Disease Source Type: research

Perioperative Complications After Noncardiac Surgery in Patients With Insertion of Second-Generation Drug-Eluting Stents
In conclusion, the incidence of perioperative complications with noncardiac surgery after second-generation DES implantation was 11% and consisted mainly of bleeding (5.8%). The incidence of definite stent thrombosis was 0.7%.
Source: The American Journal of Cardiology - May 5, 2014 Category: Cardiology Authors: Nathan Lo, Anna Kotsia, George Christopoulos, Michele Roesle, Bavana V. Rangan, Bryant J. Kim, Alexandra Webb, Subhash Banerjee, Emmanouil S. Brilakis Tags: Coronary Artery Disease Source Type: research

Meta-Analysis of Efficacy and Safety of Rivaroxaban Compared With Warfarin or Dabigatran in Patients Undergoing Catheter Ablation for Atrial Fibrillation
In conclusion, our study suggests that patients treated with rivaroxaban during periprocedural catheter ablation have similar rates of thromboembolic events and major hemorrhage. Similar results were seen in direct comparisons between dabigatran and rivaroxaban.
Source: The American Journal of Cardiology - June 9, 2014 Category: Cardiology Authors: Madan Raj Aryal, Anene Ukaigwe, Anil Pandit, Paras Karmacharya, Rajesh Pradhan, Naba Raj Mainali, Ranjan Pathak, Leena Jalota, Yashoda Bhandari, Anthony Donato Tags: Arrhythmias and Conduction Disturbances Source Type: research

Optimal Blood Pressure in Patients With Atrial Fibrillation (from the AFFIRM Trial)
Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major...
Source: The American Journal of Cardiology - June 20, 2014 Category: Cardiology Authors: Apurva O. Badheka, Nileshkumar J. Patel, Peeyush M. Grover, Neeraj Shah, Nilay Patel, Vikas Singh, Abhishek J. Deshmukh, Kathan Mehta, Ankit Chothani, Ghanshyambhai T. Savani, Shilpkumar Arora, Ankit Rathod, George R. Marzouka, James Lafferty, Jawahar L. Tags: Systemic Hypertension Source Type: research

Comparison of Safety of Left Atrial Catheter Ablation Procedures for Atrial Arrhythmias under Continuous Anticoagulation with Apixaban versus Phenprocoumon
Apixaban is increasingly used for stroke prevention in patients with atrial fibrillation (AF). Data about the safety of left atrial radiofrequency ablation procedures under continuous apixaban therapy are lacking. We performed a matched cohort study of patients undergoing LA ablation procedures for AF or left atrial flutter. For each patient on apixaban, two patients on phenprocoumon were matched by age, sex, and type of arrhythmia. The primary safety endpoint was a composite of bleeding, thromboembolic events and death.
Source: The American Journal of Cardiology - October 11, 2014 Category: Cardiology Authors: Bernhard M. Kaess, Sonia Ammar, Tilko Reents, Roger Dillier, Carsten Lennerz, Verena Semmler, Christian Grebmer, Felix Bourier, Alessandra Buiatti, Christof Kolb, Isabel Deisenhofer, Gabriele Hessling Source Type: research

Effect of an Invasive Strategy on Outcome in Patients ≥75 Years of Age with Non-ST-Elevation Acute Coronary Syndrome
The Italian Elderly ACS study was the first randomized trial (RCT) comparing an early aggressive (EA) with an initially conservative strategy in patients with NSTEACS aged ≥75 years, with the results showing no significant benefit of EA. We evaluated the outcomes of study patients, according to the treatment actually received during hospitalization. The RCT enrolled 313 patients. The primary endpoint was the composite of death, myocardial infarction (MI), disabling stroke, and repeat hospital stay for cardiovascular causes or bleeding within 1 year.
Source: The American Journal of Cardiology - December 17, 2014 Category: Cardiology Authors: Gennaro Galasso, Stefano De Servi, Stefano Savonitto, Teresa Strisciuglio, Raffaele Piccolo, Nuccia Morici, Ernesto Murena, Claudio Cavallini, Anna Sonia Petronio, Federico Piscione Source Type: research

Antithrombotic Strategies and Outcomes in Acute Coronary Syndrome with Atrial Fibrillation
Atrial fibrillation (AF) frequently occurs with acute coronary syndromes (ACS) and adds complexity to the selection of an appropriate antithrombotic strategy. We determined whether associations of antithrombotic treatment with bleeding, stroke, and death differ between ACS patients with and without AF. Olmsted County, MN residents hospitalized with incident ACS during 2005-2010 were classified according to the presence or absence of AF either prior to or during the index ACS hospitalization. Antithrombotic strategy at discharge was categorized as double/triple agents vs.
Source: The American Journal of Cardiology - January 31, 2015 Category: Cardiology Authors: Alanna M. Chamberlain, Bernard J. Gersh, Roger M. Mills, Winslow Klaskala, Alvaro Alonso, Susan A. Weston, Véronique L. Roger Source Type: research

Factors Driving Anticoagulant Selection in Patients with Atrial Fibrillation in the United States
With the introduction of novel oral anticoagulants (NOACs), the factors driving anticoagulant selection in atrial fibrillation (AF) in real-world practice are unclear. The goal was to examine whether and to what extent utilization has been driven by predictions of stroke risk (treatment benefit), bleeding risk (treatment harm), or prescription benefits’ coverage. We extracted a cohort of non-valvular AF patients initiating anticoagulation from Oct 2010-Dec 2012 from a large US database of commercial and Medicare supplement claims.
Source: The American Journal of Cardiology - February 2, 2015 Category: Cardiology Authors: Julie C. Lauffenburger, Joel F. Farley, Anil K. Gehi, Denise H. Rhoney, M. Alan Brookhart, Gang Fang Source Type: research

Meta-analysis Of Randomized Controlled Trials and Adjusted Observational Results Of Use Of Clopidogrel, Aspirin and Oral Anti-coagulants In Patients Undergoing Percutaneous Coronary Intervention
The optimal antiaggregant therapy after coronary stenting in patients receiving oral anticoagulation (OAC) is currently debated. Medline and Cochrane Library were searched for studies reporting outcomes of patients undergoing PCI and who were on triple therapy (TT)or dual antiplatelet therapy (DAPT) with aspirin and clopidogrel or dual therapy(DT) with OAC and clopidogrel. Major bleeding was the primary end point, while all-cause death, myocardial infarction (MI), stent thrombosis and stroke were secondary ones.
Source: The American Journal of Cardiology - February 11, 2015 Category: Cardiology Authors: Fabrizio D’Ascenzo, Salma Taha, Claudio Moretti, Pierluigi Omedè, Walter Grossomarra, Jonas Persson, Morten Lamberts, Willem Dewilde, Andrea Rubboli, Sergio Fernández, Enrico Cerrato, Ilaria Meynet, Flavia Ballocca, Umberto Barbero, Giorgio Quadri, Fr Source Type: research

Balancing the Risk of Bleeding and Stroke in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention (from the AVIATOR-registry)
We describe patterns and determinants of antithrombotic prescriptions in this population. The AVIATOR (Antithrombotic strategy Variability In ATrial fibrillation and Obstructive coronary disease Revascularized with PCI) Registry was an international observational study of 859 consecutive patients with AF undergoing PCI between 2009 and 2011.
Source: The American Journal of Cardiology - April 7, 2015 Category: Cardiology Authors: Marco G. Mennuni, Jonathan L. Halperin, Sameer Bansilal, Mikkel M. Schoos, Kleanthis N. Theodoropoulos, Omar A. Meelu, Samantha Sartori, Daniele Giacoppo, Chiara Bernelli, Pedro R. Moreno, Prakash Krishnan, Usman Baber, Carla Lucarelli, George D. Dangas, Source Type: research

Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry)
We describe patterns and determinants of antithrombotic prescriptions in this population. The Antithrombotic Strategy Variability in Atrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI Registry was an international observational study of 859 consecutive patients with AF who underwent PCI from 2009 to 2011.
Source: The American Journal of Cardiology - April 7, 2015 Category: Cardiology Authors: Marco G. Mennuni, Jonathan L. Halperin, Sameer Bansilal, Mikkel M. Schoos, Kleanthis N. Theodoropoulos, Omar A. Meelu, Samantha Sartori, Daniele Giacoppo, Chiara Bernelli, Pedro R. Moreno, Prakash Krishnan, Usman Baber, Carla Lucarelli, George D. Dangas, Tags: Coronary Artery Disease Source Type: research

Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin
We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin. We calculated HAS-BLED and OBRI risk scores for 2,305 patients with HFrEF in SR enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
Source: The American Journal of Cardiology - June 24, 2015 Category: Cardiology Authors: Siqin Ye, Bin Cheng, Gregory Y.H. Lip, Richard Buchsbaum, Ralph L. Sacco, Bruce Levin, Marco R. Di Tullio, Min Qian, Douglas L. Mann, Patrick M. Pullicino, Ronald S. Freudenberger, John R. Teerlink, J.P. Mohr, Susan Graham, Arthur J. Labovitz, Conrado J. Tags: Heart Failure Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10